Fundraising Fox

DMC Biotechnologies

Boulder, US · Founded 2014 · 42 employees on LinkedIn · 9 known investors

DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols. It serves specialty chemical, nutraceutical, and industrial customers seeking sustainable, cost-competitive alternatives to conventional chemical supply chains.

BiotechClimate TechNew Materials

Founders & leadership

DMC Biotechnologies was founded in 2014 by Matthew Lipscomb.

ML
Matthew LipscombFounder
JY
Josh YelenExecutive
JFJim Flatt
Jim FlattinChief Executive Officer

Board

JB
Josko BobanovicBoard director
RV
Rob van der MeijBoard director
AC
Alastair CooperBoard director
KJ
K'Lynne JohnsonBoard director
DC
Doug CameronBoard director

Investors · 9

Breakthrough Energy VenturesBoston · $500K – $50M
Sofinnova PartnersParis · $540K – $27M
Boulder Venturesreported · 3 sourcesBoulder · $1M – $4M
Capricorn Venture PartnersreportedLeuven · $270K – $10.8Mvia Rob van der Meij · board

Also in the syndicate · 5

Capricorn PartnersCibus EnterpriseleadMichelinSCGSolvay Ventures

Reported raises · per SEC filings

Form D private placements

$48.1M disclosed across 8 rounds · 2018–2025

▶$1.4MraisedDec 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Josh YelenExecutive Officer
  • Josko BobanovicDirector
  • Rob van der MeijDirector
  • K'Lynne JohnsonDirector
  • Alastair CooperDirector
  • Jim FlattExecutive Officer, Director
  • Doug CameronDirector
  • Matthew LipscombDirector
Offering amount
$2.5M
Amount sold
$1.4M
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$904.5KraisedDec 2025 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rob van der MeijDirector
  • Josh YelenExecutive Officer
  • Alastair CooperDirector
  • K'Lynne JohnsonDirector
  • Matthew LipscombDirector
  • Jim FlattExecutive Officer, Director
  • Doug CameronDirector
  • Josko BobanovicDirector
Offering amount
$1.7M
Amount sold
$904.5K
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.8MraisedApr 2025 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Doug CameronDirector
  • Rob van der MeijDirector
  • K'Lynne JohnsonDirector
  • Josh YelenExecutive Officer
  • Alastair CooperDirector
  • Matthew LipscombDirector
  • Jim FlattExecutive Officer, Director
  • Josko BobanovicDirector
Offering amount
$10M
Amount sold
$4.8M
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$66.7KraisedAug 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Doug CameronDirector
  • Josko BobanovicDirector
  • Carolyn FritzDirector
  • Michael D. LynchDirector
  • Matthew LipscombExecutive Officer, Director
  • Rob van der MeijDirector
  • Ashley JenkinsExecutive Officer
  • Alastair CooperDirector
Offering amount
$66.7K
Amount sold
$66.7K
First sale
Aug 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$33.8MraisedDec 2021 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Doug CameronDirector
  • Alastair CooperDirector
  • Rob van der MeijDirector
  • Josko BobanovicDirector
  • Matthew LipscombExecutive Officer, Director
  • Carolyn FritzDirector
  • Michael D. LynchDirector
Offering amount
$43.5M
Amount sold
$33.8M
First sale
Nov 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.4KraisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Josko BobanovicDirector
  • Rob van der MeijDirector
  • Carolyn FritzDirector
  • Michael D. LynchDirector
  • Matthew LipscombExecutive Officer, Director
  • Doug CameronDirector
Offering amount
$22.4K
Amount sold
$22.4K
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.6MraisedJun 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rob van der MeijDirector
  • Josko BobanovicDirector
  • Michael D. LynchDirector
  • Carolyn FritzDirector
  • Matthew LipscombExecutive Officer, Director
Offering amount
$12M
Amount sold
$4.6M
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedMar 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael D. LynchDirector
  • Rob van der MeijDirector
  • Matthew L. LipscombExecutive Officer, Director
  • Carolyn FritzDirector
Offering amount
$2.5M
Amount sold
$2.5M
First sale
Jan 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase II2017$600K
Department of Agriculture (USDA)Phase I2017$100K
National Science FoundationPhase ISTTR2016$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

DMC Biotechnologies Receives $34 Million Series B Funding | Global Cosmetic Industrygcimagazine.com · Dec 2021DMC Biotechnologies raises $34m in funding round led by Cibus Enterprise - FoodBev Mediafoodbev.com · Dec 2021DMC Biotechnologies closes first tranche of $34M Series B — Sofinnova Partnerssofinnovapartners.com · Dec 2021

Frequently asked questions

What does DMC Biotechnologies do?
DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols. It serves specialty chemical, nutraceutical, and industrial customers seeking sustainable, cost-competitive alternatives to conventional chemical supply chains.
Who founded DMC Biotechnologies?
DMC Biotechnologies was founded by Matthew Lipscomb in 2014.
Who are DMC Biotechnologies's investors?
DMC Biotechnologies's investors include Breakthrough Energy Ventures, Sofinnova Partners, Boulder Ventures, Capricorn Venture Partners.
How much funding has DMC Biotechnologies raised?
DMC Biotechnologies has disclosed $48.1M raised across 8 rounds.
Where is DMC Biotechnologies headquartered?
DMC Biotechnologies is headquartered in Boulder, US.